Navigation Links
Pfenex Inc. awarded a subcontract by Leidos to develop a scalable cGMP production process for a second key malaria antigen
Date:10/29/2013

SAN DIEGO, Oct. 29, 2013 /PRNewswire/ -- Pfenex Inc. today announced that Leidos Holdings, Inc. (NYSE: LDOS) (formerly SAIC) has awarded Pfenex a subcontract to develop a robust, scalable, cGMP-ready production process for large-scale production of the blood-stage malaria antigen Plasmodium falciparum reticulocyte-binding homolog 5 (Rh5). This contract is a result of successful pre-clinical studies performed by Leidos collaborators to evaluate the Rh5 antigen that was produced using the Pfēnex Expression TechnologyTM platform. The subcontract is funded with federal funds from Leidos' prime Malaria Vaccine Production and Support Services (MVPSS) contract (N01.AI.05421) from the National Institute of Allergy and Infectious Diseases (NIAID).

This is the second subcontract awarded to Pfenex for the development of critical, hard-to-express malaria antigens.  Leidos had previously awarded Pfenex a subcontract to develop a scalable, cGMP-ready production process for large-scale production of full length Circumsporozoite protein (CSP) from P. falciparum.

"We are pleased to be awarded this contract as we expand our effort to find an effective therapy for malaria," stated Bertrand C. Liang, Pfenex's Chief Executive Officer. "Pfēnex Expression TechnologyTM has once again demonstrated its ability to efficiently produce a high–value, complex protein enabling the potential of a multivalent malaria vaccine."

Pfenex will immediately commence process development activities while continuing to provide materials to Leidos and NIAID for ongoing preclinical studies. 

"Working with Pfenex and NIAID on this program is an important step in the development of an effective malaria vaccine," said James Pannucci, Ph.D
'/>"/>

SOURCE Pfenex Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pfenex Inc. and Agila Biotech Private Limited Announce Joint Venture to Develop Biosimilar Products for the Global Market
2. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
3. AMRI Awarded Development and Manufacture Contract from the UK Government
4. Numotion Awarded Best Complex Rehab Provider
5. Isis Pharmaceuticals Stanley Crooke Awarded Corporate Forums Director of the Year
6. Access Pharmaceuticals Awarded Second European Patent for MuGard
7. Jeannette R. Jakus, MD, MBA, Awarded American Academy of Dermatology Translational Biotechnology Fellowship
8. Oligomerix Awarded Phase IIB Grant From the NIH to Discover Drugs that Inhibit Alzheimers Disease Progression
9. NovelMed Awarded NIH Fast Track SBIR Grant for $1.43 Million to Advance Development of its Anti-Complement Antibody for Orphan Disease
10. Carolina Piedmont Capital Awarded VOSB Certification
11. B. Braun Awarded Premier Healthcare Alliance Contract for Dual-Source IV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)...  IP Shakti, LLC, today announced that it has changed ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... identity signifies our transformation into a company focused on patent ... patent claim validity." ... Shield™ platform, the Company commenced a corporate re-branding initiative in ...
(Date:8/28/2015)... Company plc ("Perrigo") (NYSE: PRGO ; TASE) today ... OTC brands from GSK in an all cash transaction ... demonstration of Perrigo,s unique ability to maximize brand value ... countries.  Perrigo Chairman, President and CEO ... to complete this transaction, which clearly demonstrates our ability ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4
... OMER ) today announced that it has obtained ... California to a new series of antifibrinolytic agents. These optimized ... surgical and traumatic bleeding. "This is a ... for patients. With the withdrawal of Trasylol® from the market ...
... Jan. 5, 2011 Karyopharm Therapeutics Inc., a pioneer ... modulators, announces the recruitment of a highly experienced cancer ... Chief Executive Officer. Dr. Kauffman will join Sharon Shacham, ... and Development, as its executive management team. Kauffman,s appointment ...
Cached Medicine Technology:Omeros Licenses Novel Antifibrinolytic Agents 2Omeros Licenses Novel Antifibrinolytic Agents 3Omeros Licenses Novel Antifibrinolytic Agents 4Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 2Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer 3
(Date:8/30/2015)... ... ... Lizzie’s Lice Pickers , a company that offers professional live removal ... lice head checks for just $10, which is a significant discount from the normal ... lice treatment products. “With kids returning to school, it is very important to be ...
(Date:8/30/2015)... Fl (PRWEB) , ... August 30, 2015 , ... ... Executive Vice President Jeff Fernandez will lead the expansion of global cosmeceutical and ... and skin care experience having spent the last 25 years working in operations, ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... 2015 — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The ... simple digital handwritten signature. , Clinical trial sites can now use ...
(Date:8/29/2015)... ... August 29, 2015 , ... Dr. Tim Novelli, DC., Founder and ... is to increase acceptance of the chiropractic field in the military. All too often ... Although Chiropractic was made available to the VA program over a decade ago, ...
(Date:8/29/2015)... York, NY (PRWEB) , ... August 29, 2015 ... ... successful results and include treating the localized area with stretching, soft tissue manipulation. ... a neutral pelvic position have shown through research to improve treatment outcomes. ...
Breaking Medicine News(10 mins):Health News:Lizzie’s Lice Pickers Announces Back to School Head Check Special and Discounted Lice Treatment Products 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3
... be removed ahead of time, FDA says, , , THURSDAY, ... Drug Administration warned Thursday that some medication skin patches ... MRI. , Thursday,s warning applies to brand name and ... and pain-control patches. , Some of these patches do ...
... How messages sent within stem cells through a specific communication ... cells in humans, has been discovered by scientists of the ... to be published in the March 6 issue of ... demonstrated the importance of the pathway, known as the noncanonical ...
... New Rochelle, NY, March 5, 2009Serious flaws in a ... C reduce the effectiveness of chemotherapeutic drugs in the ... of Alternative and Complementary Therapies , a journal ... This report is available free online at ...
... potential risk from exposure to medications, chemicals and other ... risks of taking cold medication or using certain cleaning ... the phone. A new Web site ( ... finding the latest information about the potential risks of ...
... therapies to restore sight, experts suggest , , THURSDAY, March ... major role in two forms of childhood blindness has ... The discovery of the link between the retinal gene ... is important because it pinpoints a new retinal metabolic ...
... top 100 property and casualty insurers closed 2008 with ... years, while the top 100 life insurers suffered unprecedented ... Data 2008 Top 100 Performance Monitor revealed a 67.7 ... the industry,s top property and casualty insurers, from $48.8 ...
Cached Medicine News:Health News:Skin Patches Can Cause Burns During MRIs 2Health News:Support for adjunctive vitamin C treatment in cancer 2Health News:New Online Service Helps Expectant Moms 2Health News:Retinal Gene Is Linked to Childhood Blindness 2Health News:Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008 2Health News:Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008 3
Inquire...
Inquire...
Agarose I (Molecular Biology Grade) - A regular melting temperature agarose for electrophoresis requiring an exceptional level of purity with unequaled performance....
... Biology Grade, is used for ... acids. It can be used ... 0.2 to 40 kb., Each ... tested and certified to be ...
Medicine Products: